聚乙二醇化重组人粒细胞刺激因子致白细胞增多的国内外文献分析

目的:分析聚乙二醇化重组人粒细胞刺激因子致白细胞增多的临床情况及特点,为临床实践提供依据及建议。方法:采用文献回顾性研究方法,对聚乙二醇化重组人粒细胞刺激因子致白细胞增多患者的临床资料进行统计分析。结果:共纳入文献13篇,涉及患者545例次。聚乙二醇化重组人粒细胞刺激因子致白细胞增多时,用药剂量以固定剂量6mg为主,兼有30,60,100,150,200μg·kg-1或固定剂量12mg,用药途径为皮下注射,不良反应发生于给药后1～11d,WBC范围为(10～230)×109·L-1。多数患者不用特殊处理,有3例需要处理的手段包括水化、血浆分离术等。结论:临床应用聚乙二醇化重组人粒细胞刺激因子时应加强用药监测,以避免和减少白细胞过高的发生。

Literature analysis of leukocytosis induced by pegfilgrastim

OBJECTIVE To analyze the clinical patterns and characteristics of leukocytosis induced by pegfilgrastim and provide the reference for clinical medication.METHODS Medical records of the leukocytosis induced by pegfilgrastim were summarized and analyzed.RESULTS A total of 13 literatures were included involving 545 ADRs. When leukocytosis happened, the main dosage of pegfilgrastim was 6 mg, including 30, 60, 100, 150, 200 μg·kg^-1 or a fixed dose of 12 mg, leukocytosis was observed usually 1-11 days after pegfilgrastim was administered subcutaneously. Most patients didn't need extra treatment, but 3 cases were treated by hydration or leukopheresis.CONCLUSION Drug monitoring should be enhanced when pegfilgrastim is used, to avoid and reduce the incidences of exorbitant leukocytosis.